Is Ipamorelin safe?

Both are GHS-R1a agonists, but the hormonal selectivity profiles differ substantially. GHRP-6 produces significant co-elevation of ACTH, cortisol, and appetite-stimulating ghrelin-like effects alongside GH release. Ipamorelin, as established in the 1998 Raun characterisation, does not meaningfully raise cortisol, ACTH, or prolactin at GH-releasing doses. In practical terms, GHRP-6 causes significant hunger and cortisol elevation; ipamorelin does not. This makes ipamorelin the preferable choice for most body composition and recovery protocols where cortisol elevation would be counterproductive.

They work at different receptors through different pathways. Sermorelin is a GHRH analog — it acts at the GHRH receptor and mimics the natural hypothalamic signal that causes GH release. Ipamorelin acts at the GHS-R1a (ghrelin receptor), a separate pathway that is partially independent of somatostatin-mediated suppression. In clinical availability, Sermorelin has a more favourable regulatory classification in the US and is currently prescribable through licensed practitioners. Ipamorelin's Category 2 status means US compounding access is restricted. The two peptides are commonly stacked because their complementary receptor pathways produce synergistic GH release.

CJC-1295 is a GHRH analog (modified GHRH 1-29) that acts at the GHRH receptor on the pituitary somatotroph cell — a different receptor from ipamorelin's GHS-R1a target. The two receptors have separate intracellular signalling pathways that, when activated simultaneously, produce greater GH release than either compound alone. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of approximately 30 minutes and is timed with ipamorelin for a combined pulse. CJC-1295 with DAC has a much longer half-life and is administered on a different schedule.

Not through licensed compounding pharmacies under current regulations. The FDA's 2023 Category 2 classification prohibits ipamorelin from being used as a bulk drug substance in compounded medications under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. It is not a scheduled controlled substance — possession is not typically criminalised — but the legal compounding pathway has been closed. Practitioners seeking similar clinical goals with legal accessibility in the US typically work with Sermorelin or tesamorelin, which are addressed in separate profiles.

The two peptides activate complementary intracellular pathways in the pituitary somatotroph cell. Ipamorelin activates GHS-R1a via the Gq/phospholipase C pathway. CJC-1295 activates GHRH-R via the Gs/adenylyl cyclase/cAMP pathway. When both pathways are activated simultaneously, they produce a supra-additive GH release — significantly greater than either compound alone. This synergy is the mechanistic basis for the stack's popularity and has been demonstrated in preclinical models.